NUCLEAR MEDICINE AND BIOLOGY 期刊简介
Nuclear Medicine and Biology publishes original research addressing all aspects of radiopharmaceutical science: synthesis, in vitro and ex vivo studies, in vivo biodistribution by dissection or imaging, radiopharmacology, radiopharmacy, and translational clinical studies of new targeted radiotracers. The importance of the target to an unmet clinical need should be the first consideration. If the synthesis of a new radiopharmaceutical is submitted without in vitro or in vivo data, then the uniqueness of the chemistry must be emphasized.
These multidisciplinary studies should validate the mechanism of localization whether the probe is based on binding to a receptor, enzyme, tumor antigen, or another well-defined target. The studies should be aimed at evaluating how the chemical and radiopharmaceutical properties affect pharmacokinetics, pharmacodynamics, or therapeutic efficacy. Ideally, the study would address the sensitivity of the probe to changes in disease or treatment, although studies validating mechanism alone are acceptable. Radiopharmacy practice, addressing the issues of preparation, automation, quality control, dispensing, and regulations applicable to qualification and administration of radiopharmaceuticals to humans, is an important aspect of the developmental process, but only if the study has a significant impact on the field.
Contributions on the subject of therapeutic radiopharmaceuticals also are appropriate provided that the specificity of labeled compound localization and therapeutic effect have been addressed.
核医学和生物学发表了针对放射性药物科学各个方面的原创研究: 合成,体外和离体研究,解剖或成像的体内生物分布,放射性药理学,放射性药物以及新的靶向放射性示踪剂的转化临床研究。目标对于未满足的临床需求的重要性应该是第一个考虑因素。如果在没有体外或体内数据的情况下提交新的放射性药物的合成,则必须强调化学的独特性。
这些多学科研究应验证定位的机制,无论探针是否基于与受体,酶,肿瘤抗原的结合,或者另一个明确的目标。研究应旨在评估化学和放射性药物特性如何影响药代动力学,药效学或治疗功效。理想情况下,该研究将解决探针对疾病或治疗变化的敏感性,尽管仅验证机制的研究是可以接受的。放射性制药实践是开发过程的一个重要方面,涉及制备,自动化,质量控制,分配以及适用于人体放射性药物鉴定和管理的法规,但前提是该研究对该领域有重大影响。
只要已经解决了标记化合物定位和治疗效果的特异性,对治疗性放射性药物的贡献也是适当的。
期刊ISSN
|
0969-8051 |
影响指数
|
2.384 |
最新CiteScore值
|
4.50 查看CiteScore评价数据 |
最新自引率
|
3.30% |
官方指定润色网址
|
https://www.deeredit.com/?type=ss1 |
投稿语言要求
|
Improve the quality of the paper, eliminate grammar and spelling errors, increase readability, ensure accurate communication of viewpoints, enhance academic reputation, and increase the chances of the paper being accepted. 建议点击这个网址:https://www.deeredit.com/?type=ss2,资深审稿专家为您评估稿件质量,提供针对性改进建议,最终可助您极大提升目标期刊录用率 |
期刊官方网址
hot |
https://www.peipusci.com/?type=9 |
杂志社征稿网址
hot |
https://www.peipusci.com/?type=10 |
通讯地址
|
ELSEVIER SCIENCE INC, 360 PARK AVE SOUTH, NEW YORK, USA, NY, 10010-1710 |
偏重的研究方向(学科)
|
医学-核医学 |
出版周期
|
Bimonthly |
出版年份
|
1993 |
出版国家/地区
|
UNITED STATES |
是否OA
|
No |
SCI期刊coverage
|
Science Citation Index Expanded(科学引文索引扩展) |
NCBI查询
|
PubMed Central (PMC)链接 全文检索(pubmed central) |
最新中科院JCR分区
|
大类(学科)
小类(学科)
综述期刊
医学
RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING(核医学)3区
否
|
|||||
最新的影响因子
|
2.384 | |||||
最新公布的期刊年发文量 |
|
|||||
总被引频次 | 82 | |||||
影响因子趋势图 |
近年的影响因子趋势图(整体平稳趋势)
|
2022年预警名单预测最新
最新CiteScore值
|
4.50
|
||||||||||||||||||
年文章数 | 64 | ||||||||||||||||||
SJR
|
0.554 | ||||||||||||||||||
SNIP
|
0.714 | ||||||||||||||||||
CiteScore排名
|
|
||||||||||||||||||
CiteScore趋势图 |
CiteScore趋势图
|
本刊同领域相关期刊
|
|
期刊名称 | IF值 |
PEDIATRIC RADIOLOGY | 2.48 |
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS | 3.068 |
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY | 3.429 |
PHYSICS IN MEDICINE AND BIOLOGY | 3.573 |
COMPUTERIZED MEDICAL IMAGING AND GRAPHICS | 4.742 |
Journal of Medical Imaging and Health Informatics | 0.62 |
RADIOLOGE | 0.629 |
RADIOLOGY | 10.994 |
RADIOGRAPHICS | 5.28 |
本刊同分区等级的相关期刊
|
|
期刊名称 | IF值 |
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY | 3.429 |
PHYSICS IN MEDICINE AND BIOLOGY | 3.573 |
COMPUTERIZED MEDICAL IMAGING AND GRAPHICS | 4.742 |
MEDICAL PHYSICS | 4.03 |
EJNMMI Research | 3.107 |
KOREAN JOURNAL OF RADIOLOGY | 3.465 |
NUCLEAR MEDICINE AND BIOLOGY | 2.384 |
EUROPEAN JOURNAL OF RADIOLOGY | 3.493 |
MOLECULAR IMAGING AND BIOLOGY | 3.453 |
分享者 | 点评内容 |